Drug Sponsors

Bridge Medicines launched to advance early technologies

Wednesday, November 2, 2016

Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical and healthcare investment firms Bay City Capital and Deerfield Management, Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases.

[Read More]

Clinigen launches Japanese business to strengthen Asian presence

Monday, October 24, 2016

Clinigen, a global pharmaceuticals and services group, has launched its Japanese business with the opening of an office in Tokyo, Japan. The establishment of Clinigen K.K. further expands the Group’s presence in Asia, following Clinigen’s acquisition of Link Healthcare in 2015. Alongside the launch, Clinigen K.K. will transfer the Marketing Authorisation for its lead Specialty Pharmaceutical (SP) product Foscavir (foscarnet sodium) back from Nobel Pharma on 1 November 2016. Nobel Pharma has been the distribution partner for Foscavir in Japan since 2011.

[Read More]

Three Questions: Ubavka DeNoble, Parexel

Monday, October 17, 2016

CWWeekly presents this feature as a spotlight on issues faced by executives in clinical research. This week, writer Karyn Korieth spoke with Ubavka DeNoble, M.D., corporate vice president at Parexel, who leads the company’s BioPharm unit, a dedi­cated team focused on the unique needs of small and mid-sized biopharmaceutical companies.

[Read More]

Merck launches Biosimilars Clarified

Friday, October 14, 2016

Merck, known as MSD outside the U.S. and Canada, has launched Biosimilars Clarified, a new educational website for patients, caregivers and the healthcare community, designed to provide clear, concise and straightforward information about biosimilar medicines.

[Read More]

Helsinn Group launches Helsinn Investment Fund

Wednesday, October 12, 2016

Helsinn, the Swiss Pharmaceutical Group focused on building quality cancer care, has introduced Helsinn Investment Fund, a fund focused on early-stage investment opportunities in areas of high unmet patient need. With an initial investment commitment of three years, followed by up to five years via follow-on rounds, the fund will have a total commitment of $50 million. The Helsinn Investment Fund is incorporated in Luxembourg and fully owned by the Helsinn Group.

[Read More]